Lacosamid Hexal

Lacosamide, the active ingredient in Lacosamid Hexal, is an anticonvulsant presented as an oral tablet for oral use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamid Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug used to manage focal seizure disorders. - Partial‑onset seizures: provides adjunctive seizure control when added to existing antiepileptic regimens. - Focal epilepsy: reduces seizure frequency in patients with refractory focal seizures. - Adjunctive therapy in epilepsy: enhances overall seizure management as part of combination therapy.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: generalized tiredness or lack of energy. - Nausea: mild to moderate stomach upset. - Headache: pressure or throbbing pain in the head. - Diplopia: temporary double vision. - Somnolence: increased sleepiness during the day.

Serious or Rare Side Effects: - Suicidal ideation: thoughts of self‑harm requiring immediate evaluation. - Severe rash or Stevens‑Johnson syndrome: skin reactions needing urgent care. - Cardiac arrhythmia: abnormal heart rhythm, especially in patients with pre‑existing conduction issues. - Hypersensitivity reactions: swelling, difficulty breathing, or anaphylaxis. - Elevated liver enzymes: potential hepatic injury indicated by lab tests. - Seizure aggravation: paradoxical increase in seizure frequency.

Before prescribing Lacosamide, clinicians should consider several safety aspects. - Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests and consider dose modification. - Cardiac conduction disorders: evaluate ECG for PR or QRS prolongation. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Driving and operating machinery: advise patients about possible dizziness or somnolence. - Store at ambient temperature (below 25°C): keep in the original container, protect from moisture.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other sodium‑channel blockers (e.g., carbamazepine, phenytoin): may increase risk of cardiac conduction abnormalities. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can markedly reduce lacosamide plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise lacosamide levels, requiring monitoring. - Oral contraceptives: lacosamide may reduce hormonal efficacy, advise alternative contraception. - Antidepressants (e.g., SSRIs): may increase risk of central nervous system depression. - Anticoagulants (e.g., warfarin): monitor INR as lacosamide can affect clotting parameters.